Hikma Pharmaceuticals PLC (HIK)

HIK

Hikma Pharmaceuticals PLC – LSE

Weekly Share Price & Valuation Overview

Market Overview

Open

1799.0000

1792.0000

High

1800.0000

Low

1785.0000

Trend

0.33641

Hikma Pharmaceuticals PLC

United Kingdom • LSE - London Stock Exchange • HIK • Currency: GBp

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Key strengths

Healthy operating margin (≥15%) indicates efficient core operations.
High gross margin (≥35%) suggests strong pricing power or cost control.
Double-digit profit margin (≥10%) supports robust bottom-line economics.
ROE ≥15% reflects strong returns on shareholder equity.

Potential weaknesses

Quick ratio <0.8 — tight near-term liquidity without inventory.

Scale & Structure Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.

Market Cap Total equity value of the company (share price × shares outstanding).: GBp 3.97B
Enterprise Value Operating value: market cap + total debt − cash.: GBp 5.30B
Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.: GBp 3.22B
Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.: GBp 1.38B
EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.: GBp 764.00M
Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).: GBp 14.57
EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).: 1.23
Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.: 3.56%
Shares Outstanding: 221.45M
Float Shares: 155.03M
Implied Shares Outstanding: 224.18M

Profitability & Efficiency TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.

Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).: 22.56%
EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).: 23.76%
Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).: 43.03%
Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).: 11.54%
ROA Return on assets: net income ÷ total assets.: 6.97%
ROE Excellent Return on equity: net income ÷ shareholder equity.: 15.38%

Growth Growth rates are YoY unless labeled QoQ.

Revenue Growth Year-over-year revenue growth.: 5.70%
Earnings Growth (YoY) Year-over-year earnings growth.: 5.90%
Earnings Growth (QoQ) Quarter-over-quarter earnings growth.: 5.30%

Liquidity & Solvency Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).

Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).: 0.65
Debt to Equity Total debt ÷ shareholder equity; leverage.: 0.61
Total Cash Cash and equivalents.: GBp 236.00M
Total Debt Short + long-term interest-bearing debt.: GBp 1.56B
Net Debt Total debt − cash (negative = net cash).: GBp 1.32B
Debt / EBITDA Leverage relative to operating earnings; lower is safer.: 2.04

Cash Flow Shown only when internally consistent; margins are TTM.

Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).: GBp 527.00M
Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.: GBp 128.12M
OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).: 16.39%
FCF Margin (TTM) Free cash flow ÷ revenue (TTM).: 3.98%
Cash Conversion (OpCF/EBITDA): 0.69

Sharemaestro House View

Confidence: 1 Risk: 2 Operational: 1 Composite Score: 1 Suggested Allocation: 1.67%

Structural Insights (experimental)

Ownership & Liquidity

Free Float 70.0%

Insiders 30.5%

Institutions 38.5%

Capital Structure

Potential Dilution

1.2%

Net Debt

GBp 1.32B

41.1% of revenue

Resilience Score 33

Methodology Notes

Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).

As of: 2025-08-18 03:46

Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.

AI generated insights not available yet. Sign in to generate the snapshot.

Please rotate your device

Menu

Weekly Share Price & Valuation Overview

Hikma Pharmaceuticals PLC